METROPOLIS
Metropolis Healthcare Limited
If management delivers what it guided
arithmetic on filed guidance and past valuations · not a price target
METROPOLIS
FY26 → FY27 · 1 year of guidance · ~0.7 years from today₹582 today
BEAR
₹466
-20%
10.8% a year · 45.9x exit
BASE
₹548
-6%
18.6% a year · 50.4x exit
BULL
₹700
+20%
25.3% a year · 60.9x exit
Where the market has priced it
45x64x today70x
- at 64x its FY26 earnings the stock already trades above the top of its own ten-year range (61x)
- this company's own median multiple sits 47% above its filed-industry peers; the scenario uses its own
How these numbers are produced
| Earnings base | FY26 fiscal year EPS ₹9.17 (screener) |
|---|---|
| Guided growth | 18.6% a year, said on the call of 11-Feb-2026 · transcript |
| Read across as | operating: guided margin x own realised revenue CAGR — medium confidence |
| Delivery calibration | 0.58x / 1x / 1.36x of what was guided — measured: 76 annual guided-vs-filed pairs + 77 near-complete quarterly years — NSE transcripts against the companies' own filings |
| Exit multiple | 45.85x / 50.41x / 60.89x, this company’s own p20 / median / p80 across 7 filed years |
| Filed-industry peers | median 34.27x across 6 peers — the cross-check, not the input |
| Arithmetic | base EPS × (1 + guided growth × delivery)1 × exit multiple |
Arithmetic on management’s own guidance and this company’s own past valuations. Not a price target, not a recommendation, and not a forecast of what the stock will do.
What management said
from a third-party research digest · not our own extraction
implied earnings growth 19%
Revised guidance to 14% to 15% CAGR in revenue for the next 3 years, 27% to 28% EBITDA margin over 3 years, and 8% to 9% patient volume growth for FY27. Maintained 12-13% organic growth for FY26 but emphasized stronger execution.
Call 11-Feb-2026 · bridge confidence medium · transcript PDF